RETA Reata Pharmaceuticals

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

Company profile

J. Warren Huff
Fiscal year end
Reata Pharmaceuticals Holdings, LLC • Reata Pharmaceuticals Global, Inc. • Reata Swiss International GmbH • Reata UK Ltd • Reata Australia Pty Limited ...

RETA stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


9 Aug 21
23 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 755.71M 755.71M 755.71M 755.71M 755.71M 755.71M
Cash burn (monthly) 7.31M (positive/no burn) 24.45M 22.69M 8.53M 12.99M
Cash used (since last report) 27.73M n/a 92.79M 86.11M 32.38M 49.29M
Cash remaining 727.98M n/a 662.92M 669.59M 723.32M 706.42M
Runway (months of cash) 99.6 n/a 27.1 29.5 84.8 54.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
16 Jun 21 Colin John Meyer Class B common Stock Class A common stock Option exercise Acquire M No No 11.62 19,525 226.88K 74,304
16 Jun 21 Colin John Meyer Employee Stock Option Class B common stock Option exercise Dispose M No No 11.62 19,525 226.88K 0
15 Jun 21 Colin John Meyer Class A common stock Sell Dispose S No No 145.9197 500 72.96K 17,000
15 Jun 21 Colin John Meyer Class A common stock Sell Dispose S No No 145.1089 1,217 176.6K 17,500
15 Jun 21 Colin John Meyer Class A common stock Sell Dispose S No No 143.9818 2,483 357.51K 18,717
15 Jun 21 Colin John Meyer Class A common stock Sell Dispose S No No 142.8332 8,867 1.27M 21,200
15 Jun 21 Colin John Meyer Class A common stock Sell Dispose S No No 142.0762 12,518 1.78M 30,067
15 Jun 21 Colin John Meyer Class A common stock Sell Dispose S No No 141.0923 6,494 916.25K 42,585
15 Jun 21 Colin John Meyer Class A common stock Sell Dispose S No No 139.9779 4,107 574.89K 49,079
15 Jun 21 Colin John Meyer Class A common stock Sell Dispose S No No 139.1354 3,814 530.66K 53,186

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

92.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 195 197 -1.0%
Opened positions 36 36
Closed positions 38 40 -5.0%
Increased positions 68 77 -11.7%
Reduced positions 66 53 +24.5%
13F shares
Current Prev Q Change
Total value 4.11B 3.11B +32.2%
Total shares 29.05M 27.78M +4.6%
Total puts 335.7K 379.2K -11.5%
Total calls 159K 264.9K -40.0%
Total put/call ratio 2.1 1.4 +47.5%
Largest owners
Shares Value Change
Wellington Management 4.33M $612.33M -0.7%
CPMG 2.9M $410M 0.0%
IVZ Invesco 2.81M $397.66M +36.6%
Rose William 2.76M $389.19M 0.0%
Vanguard 2.54M $359.28M +4.3%
BLK Blackrock 2.14M $302.28M +43.9%
BEN Franklin Resources 1.39M $196.44M -4.9%
TROW T. Rowe Price 1.07M $150.74M +1.1%
FMR 749.93K $106.14M +1130.8%
DB Deutsche Bank AG - Registered Shares 645.28K $91.33M +6.2%
Largest transactions
Shares Bought/sold Change
IVZ Invesco 2.81M +753.36K +36.6%
FMR 749.93K +689K +1130.8%
BLK Blackrock 2.14M +651.77K +43.9%
Pictet Asset Management 99.16K -252.4K -71.8%
Cormorant Asset Management 168.15K -231.85K -58.0%
STT State Street 589.49K +209.1K +55.0%
GS Goldman Sachs 61.88K -169.87K -73.3%
Sofinnova Investments 79.6K -158.92K -66.6%
NTRS Northern Trust 289.1K +157.28K +119.3%
Candriam Luxembourg S.C.A. 0 -151.71K EXIT

Financial report summary

Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes and other financial information appearing in this Quarterly Report on Form 10-Q.  Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, operations, and product candidates, includes forward-looking statements that involve risks and uncertainties.  Factors that may cause actual results to differ materially from current expectations include, among other things, those described under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” and discussed elsewhere in this Quarterly Report on Form 10-Q.
  • We are a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies that change patients’ lives for the better.  We concentrate on small-molecule therapeutics with novel mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies.  Our lead programs are in rare forms of CKD and a rare neurological disease.  We announced positive topline data from registrational trials for both of our lead product candidates, bardoxolone in patients with CKD caused by Alport syndrome and omaveloxolone in patients with a neurological disorder called Friedreich’s ataxia (FA).  Both bardoxolone and omaveloxolone activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation.  Because mitochondrial dysfunction, oxidative stress, and inflammation are features of many diseases, we believe bardoxolone and omaveloxolone have many potential clinical applications.  We possess exclusive, worldwide rights to develop, manufacture, and commercialize bardoxolone, omaveloxolone, and our next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone in certain indications, which are licensed to KKC.
Content analysis
H.S. sophomore Avg
New words: abatement, absolute, absorption, accurate, add, adding, adhere, ADME, agenda, ANCOVA, artificially, biological, bioresearch, Chemistry, clarified, CMC, comment, confounded, conventional, core, covariance, covariate, coverage, COVID, customary, cutoff, dataset, detail, deviate, dispensation, doubled, driven, earlier, ease, educate, educating, education, efficient, efficiently, empirically, encouraged, error, exceeded, excretion, extreme, falling, feedback, figure, flexible, force, formal, goal, greater, hired, hub, inclusion, independent, inflated, infrastructure, inquiry, inspection, interpretation, invited, irrespective, irreversible, IRS, July, Labour, Lastly, Levey, manifestation, meaningfully, methodology, MHLW, Ministry, missing, NaN, nonclinical, notable, Notably, partner, payer, pharmacodynamic, pharmacy, Plasma, plausibility, pre, prespecified, prevalent, proceeding, proportion, reinitiated, relevant, repeated, REPRISE, resolution, restarted, role, rolled, sample, slight, slower, sparse, specialty, step, team, tentatively, timepoint, tolvaptan, trajectory, twelve, unblind, unblinding, voluntary, Welfare, window, withdrew, yearly
Removed: attributable, basic, borrowing, computation, hold, integrity, randomize, ratable, screen, serve, write